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BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to the fields of Surface 
Enhanced Raman Scattering (SERS) using a single and arrays 
of nanoplasmonic resonators for detection of enzymatic 
activity. The present invention relates specifically to the 
detection of protease activity, such as the Prostate Specific 
Antigen (PSA) and Proteolytically Active PSA for diagnostic 
applications in prostate cancer. 
2. Related Art 
Originally developed in 1928, Raman spectroscopy has 
been used extensively to characterize molecular properties 
(Kazuo Nakamoto John R. Ferraro, Chris W. Brown, Intro-
ductory Raman Spectroscopy, 2nd ed. (Elsevier Science, 
2003). Surface-Enhanced Raman Spectroscopy (SERS) 
increases the Raman signal significantly (C. R. Yonzon, C. L. 
Haynes, X. Zhang et al., Anal Chem 76 (1), 78 (2004); A. E. 
Grow, L. L. Wood, J. L. Claycomb et al., JMicrobiolMethods 
53 (2),221 (2003); K. Nithipatikom, M. J. McCoy, S. R. Hawi 
et al., Anal Biochem 322 (2),198 (2003); T B. Jackson and N. 
J. Halas, P Natl Acad Sci USA 101 (52), 17930 (2004)) 
through enhanced electromagnetic fields in close proximity 
to a surface. SERS measurements performed on rough metal 
surface or dispersed metal nanoparticle aggregates have 
shown the highest Raman enhancement factors up to 10 14 for 
detection down to single molecule level (Katrin Kneipp, 
Harald Kneipp, Irving Itzkan et al., Current Science (Banga-
lore) 77 (7), 915 (1999); S. Nie and S. R. Emory, Science 275 
(5303), 1102 (1997)) but these measurement often suffer 
from poor reproducibility (M. Mo skovits, Reviews of Modern 
Physics 57 (3), 783 (1985)). To improve the reproducibility, 
other methods including self-assembly of metallic colloidal 
nano-particles (R. G. Freeman, K. C. Grabar, K. J. Allison et 
al., Science 267 (5204), 1629 (1995)), nanosphere lithogra-
phy (NSL) and metal film over nanosphere (MFON) (C. L. 
Haynes and R. P. Van Duyne, Journal ofPhysical Chemistry 
B 107 (30), 7426 (2003)), electrochemical roughening of 
polished gold substrate (J. M. Sylvia, J. A. Janni, J. D. Klein 
et al., Analytical Chemistry 72 (23), 5834 (2000)), and peri- 
5 odic structured metallic substrate using electron-beamlithog-
raphy (M. Kahl, E. Voges, S. Kostrewa et al., Sensors and 
Actuators B-Chemical 51 (1-3), 285 (1998)), have been 
developed to fabricate SERS substrate consisting homoge-
neous features over large area with reproducible enhance- 
10 ment factors up to 10 8 . Although these efforts lead to success-
ful utilization of SERS analysis in many promising 
applications including gene and protein discrimination (Y. C. 
Cao, R. C. Tin, J. M. Nam et al., JAm Chem Soc 125 (48), 
14676 (2003); Y. W. C. Cao, R. C. Tin, and C. A. Mirkin, 
15 Science 297 (5586), 1536 (2002); T. Vo-Dinh, F. Yan, and M. 
B. Wabuyele, Journal ofRaman Spectroscopy 36 (6-7), 640 
(2005)), bio-warfare agents detection (D. A. Stuart, K. B. 
Biggs, and R. P. Van Duyne, Analyst 131 (4), 568 (2006)) and 
real-time glucose monitoring (O. Lyandres, N. C. Shah, C. R. 
20 Yonzon et al., Analytical Chemistry 77 (19), 6134 (2005)), 
lacking of the ability to fabricate SERS hot-spots at specific 
location limits application for very small sample volume. 
To overcome such limit, we recently developed tunable 
nanoplasmonic resonators (NPRs), consisting of thin S'0 2 
25 layer sandwiched between metallic nano-disks described in 
Durant S. Su K, Steel M. J., Xiong Y. Sun C., Zhang X, 
Journal ofPhysical Chemistry B 110 (9),3964 (2006) hereby 
incorporated by reference. The resonance frequency can be 
precisely tuned by varying the dielectric layer thickness and 
3o aspect-ratio of the NPRs. Individual NPRs can enhance the 
Raman intensity by a factor of 6.1x10 10 ; among the largest 
values obtained for a single SERS substrate or nanoparticle. 
Fabricated using well established nanolithography processes, 
the NPR-based method enables producing SERS hot-spots at 
35 desired location in a much smaller dimension reproducibly, 
allowing multiplexed high throughput detection and lab-on-
chip applications. 
Prostate cancer biomarker Prostate Specific Antigen 
(PSA), a kallikrein (hK) family serine protease (S. R. Den- 
40 meade and J. T. Isaacs, BJUInt 93 Suppl 1, 10 (2004); J. A. 
Clements, N. M. Willemsen, S. A. Myers et al., Crit Rev Clin 
Lab Sci 41 (3), 265 (2004)), is used as a model protease in the 
present application. The commonly used prostate-specific 
antigen (PSA) blood test has being widely used for early 
45 diagnosis and management of prostate cancer, the leading 
male cancer (H. Gronberg, Lancet361 (9360), 859 (2003); S. 
R. Denmeade and J. T. Isaacs, Nat Rev Cancer 2 (5), 389 
(2002)). However, serum PSA concentrations reflect the pres- 
ence of benign prostatic hyperplasia (BPH) more often than 
50 cancer (A. Caplan and A. Kratz, Am JClin Pathol 117 Suppl, 
S104 (2002); E. I. Canto, S. F. Shariat and K. M. Slawin, 
Curr Urol Rep 5 (3), 203 (2004)). The lack of specificity 
causes a high false-positive rate and often leads to costly 
prostate needle biopsies for diagnosis and post-biopsy com- 
55 plications as well as considerable anxiety (M. B. Gretzer and 
A. W. Partin, Urol Clin North Am 30 (4), 677 (2003); A. 
Haese, M. Graefen, H. Huland et al., Curr Urol Rep 5 (3),231 
(2004)). Recent research has identified a family of highly 
specific peptides that can be cleaved by paPSA isoform in 
60 xenografts models (S. R. Denmeade, C. M. Jakobsen, S. 
Janssen et al., J Natl Cancer Inst 95 (13), 990 (2003)) and 
human samples (P. Wu, U. H. Stenman, M. Pakkala et al., 
Prostate 58 (4), 345 (2004); P. Wu, L. Zhu, U. H. Stenman et 
al., Clin Chem 50 (1), 125 (2004)) thus, measurement of 
65 paPSA protease activity from in vivo samples is possible and 
would be potentially valuable as a more specific screening 
agent for prostate cancer and in detection of recurrent disease. 
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4 
However, reported results based on immunopeptidemetric 	 in a microarray or nanoarray format is contemplated. In addi- 
assays (IMPA) exhibit low fluorescence signal-to-noise 	 tion, the magnetic or laser maneuverability allow biosensing 
ratios, preventing reliable measurements at lower concentra- 	 at desired locations, which would be useful for obtaining in 
tions in the clinically important range of 60-300 pM (P. Wu, 	 situ measurements intracellularly. 
U. H. Stenman, M. Pakkala et al., Prostate 58 (4),345 (2004); 5 	 In another embodiment, the nanosensor herein described 
P. Wu, L. Zhu, U. H. Stenman et al., Clin Chem 50 (1), 125 	 may be integrated into microfluidics system or other chip 
(2004)). In addition, there is usually a limited number of 	 system. In one embodiment, the nano sensor-based assay can 
prostate cancer cells (<1000) isolated from fine needle biopsy 	 be performed in liquid phase, wherein the sample is contacted 
or circulating cell capture. No commercial method exists that 	 with the NPR nanosensor or the NPR array and the SERS 
can perform a paPSA protease activity assay on a small num-  10 measurements can be conducted. 
ber of cells for clinical staging. Therefore, one goal of the 
present invention is to provide a method that allows specific 	 DESCRIPTION OF THE DRAWINGS 
and sensitive measurements of paPSA for prostate cancer 
detection in a very small sample volume. 	 FIG. 1 Schematic illustration of the working principle of 
15 detecting PSA protease activity using peptide-conjugated 
BRIEF SUMMARY OF THE INVENTION 
	
NPR SERS nanosensors. (a) NPRs exhibit a tunable plasmon 
resonance and highly enhanced local electromagnetic field 
The present invention provides the detection and measure- 	 through coupled plasmonic resonance. NPRs with a short axis 
ment of enzymatic activity in vitro and, in situ, using a 	 of 150 mn and long axis of 200 mn were made of multi-stacks 
nanosensor comprised of a nanoplasmonic resonator (NPR) 20 of silver and S'02 layers with thicknesses of 25 mn and 5 mu, 
with at least picomolar sensitivity. In one embodiment, a 	 respectively. (b) The molecular structure of the biomarker 
bioconjugated NPR enhances Raman spectra intensity in Sur- 	 that consists of Raman dye R19, PSA specific peptide 
face-Enhanced Raman Spectroscopy (SERS) and enables 	 sequence HSSKLQLAAAC (SEQ ID NO: I), and cysteine. 
sensitive single-step detection of enzymatic activity in 	 The peptide can be cleaved by PSA enzyme between 
extremely small volume. 	 25 HSSKLQ and LAAAC. (c) The detection scheme of NPR 
In certain preferred embodiments, the invention provides a 	 functionalized with peptide sequence HSSKLQLAAAC 
nanosensor, comprising a nanoplasmonic resonance SERS 
	 (SEQ ID NO: 1) and the Raman dye R19 (star). The presence 
platform. The platform comprising a substrate featuring a 	 of the PSA enzyme will cleave the peptide sequence. After 
surface enhanced Raman scattering (SERS) nanoplasmonic 	 cleavage, the diffusion of the R19 (star) away from the surface 
resonator singly or in an array, wherein the nanoplasmonic 30 will be monitored by the loss of the SERS signatures of the 
resonator (NPR) has a biomolecule conjugated thereto. In one 	 R19 moiety. Packing molecule octanethiol (HS (CH 2)a 
embodiment, the NPR comprising metallic nanodisks with 
	
CH,) was used to reduce the packing density of the reporting 
alternating shielding layer(s), having a tagged biomolecule 	 peptide on NPR surface, and thus, allows PSA enzyme to 
conjugated or tethered to the surface of the NPR. In a pre- 	 access the reporting peptide. (d) Optical microscopic image 
ferred embodiment, the tag is a Raman active tag. 	 35 of NPRs arrays fabricated using standard e-beam lithography 
In one embodiment, the biomolecule is a peptide linked to 	 and thin film deposition process. Fabricated NPRS arrays 
a Raman active tag, wherein the peptide comprising a specific 	 consists of 3000 NPRs with 500 mn spacing. Multiple NPRs 
sequence that can be specifically modified or cleaved by an 	 arrays and alignment mark can be conveniently fabricated on 
enzyme. Thus, this peptide-conjugated nanoplasmonic reso- 	 the same substrate. (e) Magnified image of NPR array mea- 
nator is intended to be used as a specific screening tool to 40 sured by Scanning Electron Microscope. Using precision 
provide information on the presence, concentration and activ- 	 lithography methods, the NPR can be prepared in a controlled 
ity of enzymes such as proteases, kinases and peptidases. In 	 manner. (f) Image of NPRs measured at higher magnification 
one embodiment, the screen would measure activity of cancer 	 using Atomic Force Microscope (AFM). (g) Measured 
biomarkers such as prostate-specific antigen (PSA) in a bio- 	 extinction spectrum of an NPR array at a wavelength range of 
logical sample. In one embodiment, the peptides should be 45 425 to 650 mu. The resonance peak of the NPR has been tuned 
substrates specifically recognized, modified and/or acted on 	 to closely match the laser excitation and Raman emission 
by the corresponding enzyme to be detected. 	 frequencies, and thus, maximize the overall enhancement of 
In another embodiment, real-time reaction monitoring also 	 the Raman signal. (h) Highly reproducible Raman spectra of 
provides critical information on enzyme activity rather than 	 para-mercaptoaniline (pMA) molecules conjugated on NPR 
just measuring the presence of the protein. Different Raman 50 surface measured at different NPRs arrays. Integration time is 
tag molecules may be used such that detection of two or more 	 30 seconds. 
types of enzymes may be carried out by multiplexing peptide- 	 FIG. 2 Real-time kinetic measurement of PSA protease 
conjugated NPRs. Furthermore, an array of the peptide-con- 	 activity. (a) SERS spectra for 6 nM PSA incubation taken over 
jugated NPRs on a substrate is described for use to further 	 30 minutes with an integration time of 30 seconds. (b) SERS 
amplify or expand detection. 	 55 spectra for the negative control, 6 nM granzyme B, taken over 
In another embodiment, different biomolecule substrates 	 30 minutes. (c) Time-resolved measurements of relative 
orthogonal to each other, or with minor overlap in specificity, 	 change in Raman peak intensity at 1316 crn i , 1456 crn i , 
can be used to detect the corresponding enzyme. In one 	 1526 crn i , and 1597 cm- ' before and after addition of PSA 
embodiment, a biomolecule library can be conjugated to the 	 protease. Negative time represents time before protease addi- 
NPRs and spatially separated in either a random array or 60 tion. 
ordered microarray format. The multiplexed array of the bio- 	 FIG. 3 Time-resolved measurements of PSA activity by 
molecule-nanoplasmonic resonators can be used to detect 	 varying the active PSA concentration. (a) Normalized SERS 
multiple enzymes simultaneously. 	 intensity change for 1316 cm - ' peak at active PSA concen- 
The NPR can also be manipulated by laser or magnetic 	 tration from 6 pM to 6 nM. The decreasing of SERS intensity 
fields to address at high accuracy spatially, so that it could be 65 can be clearly measured while no significant change can be 
multiplexed as high density arrays (with sub-microliter vol- 	 observed in the control experiment with no active PSA pro- 
ume). Additional spatial multiplexing for multiple proteases 	 tease. (b) Concentration dependence of normalized SERS 
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intensity change obtained at 30 min. (c) Protease activity 
measurement obtained from unprocessed extracellular fluid 
(ECF): Raman spectra obtained at the beginning of exposing 
LNCaP cells (positive control) ECF to NPR nanosensors (t -0 
min) and after 30 minutes. (d) Normalized change of SERS 5 
intensity at 1316 cm - ' peak indicating PSA proteolytic activ-
ity in the fluid extracted from LNCaP and K562 cell lines. 
FIG. 4. PSA detection scheme using Raman detection and 
spectroscopy. 
FIG. 5A. A SERS microspectroscopy system and nano- 10 
plasmonic resonator visualization and real-time enzyme reac-
tion detection. FIG. 5B. A schematic of an optical spectrum 
measurement setup. 
FIG. 6 (A) Simulated scattering spectra for single nano-
disks with various metal layers. The nanodisk is circular with 15 
a 90 nm diameter, while the total thicknesses for metal layers 
and S'02 layers are kept both at 30 mu. The polarization of the 
incident light is polarized in the Y-axis direction. (B) Y-Z 
plane cross section of local electrical field distribution for the 
single An layer nanodisk (S'0 2/Au/S'02) at the resonant fre- 20 
quency. (C) Y-Z plane cross section of local electrical field 
distribution for the 6 An layer nanodisks (SiO2/Au) 6/S'O2 at 
resonant frequency. 
DETAILED DESCRIPTION OF THE PREFERRED 25 
EMBODIMENT 
The present invention demonstrates the in vitro detection 
and measurement of enzymatic activity using a nanosensor 
comprised of a nanoplasmonic resonator (NPR) with at least 30 
picomolar sensitivity. In one embodiment, a bioconjugated 
NPR enhances Raman spectra intensity in Surface-Enhanced 
Raman Spectroscopy (SERS) and enables sensitive single-
step detection of enzymatic activity in extremely small vol-
ume. 35 
One of the major advantages and applications of the small 
volume property is that it is useful in detecting proteases such 
as prostate-specific antigen (PSA) activity of cancer cells at 
single cell level. The small volume requirement and sensitiv-
ity level makes it possible to detect PSA activity in captured 40 
circulating prostate cancer cells for indications of various 
disease states, e.g., metastasis, which is not feasible with 
conventional techniques. In semen, the PSA concentration is 
10-150 µM, with approximately two thirds of the PSA enzy-
matically active. The sensitivity level achieved with the NPR 45 
PSA probe (nanomolar range) is sufficient for a seminal fluid 
based assay, thus the nanoplasmonic resonance SERS plat-
form described herein is intended to have clinical applica-
tions. 
In a preferred embodiment, the invention provides a 50 
nanosensor, comprising a nanoplasmonic resonance SERS 
platform. The platform comprising a substrate featuring a 
surface enhanced Raman scattering (SERS) nanoplasmonic 
resonator singly or in an array, wherein the nanoplasmonic 
resonator (NPR) has a biomolecule conjugated thereto. In one 55 
embodiment, the NPR comprising at least two nanodisks with 
an alternating thin shielding layer(s), and a tagged biomol-
ecule conjugated or tethered to the surface of the NPR. In a 
preferred embodiment, the tag is a Raman active tag. 
A variety of detection units of potential use in Raman 60 
spectroscopy are known in the art and any known Raman 
detection unit may be used. A non-limiting example of a 
Raman detection unit is disclosed in U.S. Pat. No. 6,002,471. 
In this example, the excitation beam is generated by either a 
Nd:YAG laser at 532 nm (nanometer) wavelength or a Ti: sap- 65 
phire laser at 365 nm wavelength. Pulsed laser beams or 
continuous laser beams may be used. The excitation beam 
6 
passes through confocal optics and a microscope objective, 
and may be focused onto a substrate containing attached 
biomolecule targets. Raman emission light target(s) can be 
collected by the microscope objective and the confocal 
optics, coupled to a monochromator for spectral dissociation. 
The confocal optics can include a combination of dichroic 
filters, barrier filters, confocal pinholes, lenses, and mirrors 
for reducing the background signal. Standard full field optics 
can be used as well as confocal optics. 
The Raman emission signal can be detected by a Raman 
detector. The detector can include an avalanche photodiode 
interfaced with a computer for counting and digitization of 
the signal. Where arrays of target(s) are to be analyzed, the 
optical detection system may be designed to detect and local-
ize Raman signals to specific locations on a chip or grid. For 
example, emitted light may be channeled to a CCD (charge 
coupled device) camera or other detector that is capable of 
simultaneously measuring light emission from 20 multiple 
pixels or groups of pixels within a detection field. 
Various excitation sources include, but are not limited to, a 
nitrogen laser (Laser Science Inc.) at 337 mn and a helium-
cadmium laser (Liconox) at 325 mn (U.S. Pat. No. 6,174, 
677). The excitation beam can be spectrally purified with a 
bandpass filter 30 (Corion) and may be focused on a substrate 
140 using a 6x objective lens (Newport, Model L6X). The 
objective lens can be used to both excite the indicator(s) and 
to collect the Raman signal, by using a holographic beam 
splitter (Kaiser Optical Systems, Inc., Model FIB 647-26N18) 
to produce a right-angle geometry for the excitation beam and 
the emitted Raman signal. A holographic notch filter (Kaiser 
Optical Systems, Inc.) can be used to reduce Rayleigh scat-
tered radiation. Alternative Raman detectors include, but are 
5 not limited to, an ISA HR-320 spectrograph equipped with 
a red-enhanced intensified charge-coupled device (RE-
ICCD) detection system (Princeton Instruments). Other types 
of detectors may be used, such as charged injection devices, 
photodiode arrays or phototransistor arrays 
Referring now to FIG. 1A, the nano scale dimension and the 
high local electromagnetic field enhancement of the NPR 
enables a high-sensitivity optical detection of biomolecular 
reactions on its surface. In a preferred embodiment, the nano-
plasmonic resonators are lithographically defined metallodi-
electric nanoparticles comprising at least two nanodisks 
stacked vertically, separated by a shielding layer. In various 
embodiments, the NPR are preferably patterned on a sub-
strate by electron beam lithography or other lithographic 
methods known in the art. 
The substrate on which the NPRs are patterned can be 
comprised of quartz, polystyrene, silica, dextran, or any other 
materials with constant Raman spectra. In one embodiment, 
to prevent charging effects during the electron beam lithog-
raphy, the substrate is further coated with a layer such as 
indium tin oxide. The layer can be sputtered, deposited coated 
or added using any other method onto the substrate to form a 
thin film. In another embodiment, the substrate is then spin-
coated with a polymer to create a positive photoresist before 
exposure to create the patterns. In one embodiment, after 
exposure, patterns are developed using a solvent mixture, 
followed by multilayer electron beam evaporation and stan-
dard lift-off procedure. 
In one embodiment, the NPRs are made as described in 
Example 1. In another embodiment, the NPRs are made as 
described in K. H. Su, Q. H. Wei, and X. Zhang, "Tunable and 
augmented plasmon resonances of Au/S'0 2/Au nanodisks", 
Appl. Phys. Lett. 88, 063118, 2006; and Kai-Hung Su, 
Stephan Durant, Jennifer M. Steele, Yi Xiog, Cheng Sun, 
and Xiang Zhang, Raman Enhancement Factor of a Single 
US 8,685,743 B2 
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Tunable Nanoplasmonic Resonator, Journal of Physical 	 Non-limiting examples of tag molecules include TRIT (tet- 
Chemistry B, 110 (9), 3964 (2006), both of which are hereby 	 ramethyl rhodamine isothiol), NBC (7-nitrobenz-2-oxa-1,3- 
incorporated by reference in their entirety. 	 diazole), Texas Red dye, phthalic acid, terephthalic acid, 
In a preferred embodiment, the nanoplasmonic resonator i s 	 isophthalic acid, cresyl fast violet, cresyl blue violet, brilliant 
comprised of nanodisks layered or stacked with an alternating 5 cresyl blue, para-aminobenzoic acid, erythrosine, biotin, 
shielding layer. For example, NPRs can be made having two 	 digoxigenin, 5-carboxy-4',5'-dichloro-2',7'-dimethoxy fluo- 
nanodisks of gold with a shielding layer of S'0 2 sandwiched 	 rescein, 5-carboxy-2',4 1 ,5 1 ,7'tetrachlorofluorescein, 5-car- 
in between. In another embodiment, the two nanodisks of 
	
boxyfluorescein, 	 5-carboxy 	 rhodamine, 	 6-carbox- 
gold with a shielding layer of S'0 2 sandwiched in between is 	 yrhodamine, 	 6-10 	 carboxytetramethyl 	 amino 
capped on one end with another shielding layer of S'0 21  io phthalocyanines, 6-carboxy-X-rhodamine, azomethines, 
thereby producing an S'0 2/Au/S'02/Au nanoplasmonic reso- 	 cyanines, xanthines, succinylfluoresceins, aminoacridine, 
nator. 	 and cyanide (CN), thiol (SIT), chlorine (el), bromine (Br), 
In one embodiment, the nanoscale layers are evaporated on 	 methyl, phorphorus (P), sulfur (S), SN, Al, Cd, Eu, Te, and 
the patterned substrate to form the nanodisk layers of the 	 compounds containing such moieties. In certain embodi- 
NPRs. In a preferred embodiment, each nanodisk is 50-500 15 ments, carbon nanotubes, quantum dots (see, e.g., Evident 
mu at its widest point. The nanodisks can be comprised of a 	 Technologies, Troy N.Y.; Invitrogen/Molecular Probes, 15 
thin layer of a metal, a semiconductor material, multi-layers 	 etc.), or microspheres (e.g. fluorescent microspheres (see, 
of metals, a metal oxide, an alloy, a polymer, or carbon nano- 	 e.g. Transfluosphres(k from InvitrogenlMolecular Probes) 
materials. In certain embodiments the nanodisk(s) comprise a 	 can be used as Raman tags. 
metal selected from the group consisting of Ga, Au, Ag, Cu, 20 In various embodiments, one or more Raman labels (Ra- 
Al, Ta, Ti, Ru, Ir, Pt, Pd, Os, Mn, Hf, Zr, V, Nb, La, Y, Gd, Sr, 	 man tags) can be attached to the biomolecule (e.g., polypep- 
Ba, Cs, Cr, Co, Ni, Zn, Ga, In, Cd, Rh, Re, W, Mo, and oxides, 	 tide) that is attached to the NPR(s). The presence of such 
and/or alloys, and/or mixtures, and/or nitrides, and/or sin- 	 Raman tags can enhance the change in Raman signal pro- 
tered matrix thereof. 	 duced by cleavage of the peptide. 
The shielding layer of material can be any material having 25 	 Thus, in one embodiment this Raman tagged biomolecule- 
a constant Raman spectra. The shielding layer functions as a 	 conjugated nanoplasmonic resonator is intended to be used as 
tuning parameter for plasmon resonant frequency of the NPR. 	 a specific screening tool to provide information on the pres- 
Compared to single layered metallic nanodisks, multilayered 	 ence, concentration and enzymatic activity of enzymes and 
nanodisks exhibit several distinctive properties including sig- 	 other cancer biomarkers, such as prostate-specific antigen 
nificantly enhanced plasmon resonances and tunable reso-  30 (PSA) in a biological sample. In certain embodiments, the 
nance wavelengths which can be tailored to desired values by 	 biomolecule is a peptide. The terms "polypeptide," "peptide" 
simply varying the dielectric layer thickness while the par- 	 and "protein" are used interchangeably herein to refer to a 
ticle diameter is kept constant. Numerical calculations show 	 polymer of amino acid residues. The terms apply to amino 
that slicing one metal layer into metal multilayers leads to 	 acid polymers in which one or more amino acid residue is an 
higher scattering intensity and more "hot spots," or regions of 35 artificial chemical mimetic of a corresponding naturally 
strong field enhancement. FIG. 6 shows a color simulated 	 occurring amino acid, as well as to naturally occurring amino 
scattering spectra for nanodisks with various metal layers. 	 acid polymers and non-naturally occurring amino acid poly- 
Thus, in another embodiment, each nanodisk layer in the 	 mer. In certain embodiments, multiple peptides are conju- 
NPR can be the same or different thickness. By choosing 	 gated to the surface of the nanoscrescent, each being the same 
different layer thicknesses, the plasmon resonance wave-  40 or different. In various embodiments approximately 5 to 500, 
length and the surface enhancement factor can be tuned to 	 more preferably about 10 to about 400, still more preferably 
match various applications. For instance, in Example 1, NPRs 	 about 20, 30, or 40 to about 200, 250, or 300, and most 
with a short axis of 150 nm and long axis of 200 nm were 	 preferably about 50 to about 150 substrate molecules (e.g. 
made of multi-stacks of silver and S'0 2 layers with thick- 	 peptides) are attached to the nanocrescent. In one embodi- 
nesses of 25 nm and 5 nm, respectively. Furthermore, by 45 ment, about 100 peptides are 15 conjugated to the nanocres- 
selective shielding of the outer surface of the metallic struc- 	 cent with direct reaction between An and the thiol group on 
ture, the efficiency can be further enhanced by guiding the 	 the Peptide. 
molecular assembly to the locations that exhibit strong elec- 	 The enzyme whose activity is being monitored can include 
tromagnetic fields. Thus, in another embodiment, the outer 	 but is not limited to, an enzyme, protease, kinase, peptidase or 
layers are shielding layers comprising material having a con-  50 other biological molecule. In various embodiments, the bio- 
stant Raman spectra. FIG. lA shows the schematics and 	 molecules are peptides specifically recognized and modified 
transmission electron micrograph of a preferred nanoplas- 	 or cleaved by the corresponding enzyme to be detected. In 
monic resonator (NPR). 	 another embodiment, the biomolecules are peptides specifi- 
In one embodiment, the biomolecule is a peptide compris- 	 cally recognized and phosphorylated by the kinase to be 
ing a specific sequence that can be specifically cleaved by 55 detected. Various types ofproteases and peptides specifically 
protease, linked to a Raman active tag. 	 recognized by those proteases are also described in co-pend- 
A variety of Raman labels are known in the art (e.g., U.S. 	 ing International Application No. PCT/US2007/010722, 
Pat. Nos. 5,306,403; 6,002,471; 6,174,677, which are incor- 	 entitled "Detection of Protease and Protease Activity Using a 
porated herein by reference) and any such known Raman 	 Single Nanoscrescent SERS Probe." Related methods using a 
labels) can be used. The labels typically have characteristic 6o nanocrescent probe for SERS detection of a protease or other 
(e.g., unique) and highly visible/detectable optical signa- 	 biomolecules is also described in PCT/US2007/010722, 
tures. Suitable Raman labels include, but are not limited to 	 which is hereby incorporated by reference for all purposes. 
fluorophore, a chromophore, a quantum dot, a fluorescent 	 In a preferred embodiment, the biomolecule is a peptide, 
microsphere, biotin, and the like. In certain embodiments the 	 wherein the peptide is an oligopeptide about 10-12 amino 
Raman label comprises a Rhodamine, a fluoresceine, or an 65 acid residues in length. However, the peptide can be as short 
exogenous chemical molecule. In certain embodiments the 	 as 4 amino acid residues, and as long as 100 amino acids. In 
Raman label comprises a moiety acting as a Raman tag. 	 one embodiment, the peptides should be sequences specifi- 
Illustrative proteases and protease recognition sites (* indicates 
the peptide bond being hydrolyzed). 
45 protease 
Family 	 Protease 	 Protease Recognition Sites 
factor Xa Ile-Gly-Gly-Arg* 
trypsin Lys*, Arg* 
chymotrypsin Tyr*, Phe*, Leu*, Ile*, 
Val*, Trp*, and His* at high pH 
thrombin Arg* 
PSA 
peanut mottle polyvirus Glul-Xaa-Xaa-Tyr- 
Nla protease Gln*(Ser/Gly) 
papame 
bromelaine 
cathepsin B 
cysteine cathepsin L 
aspartyl HIV protease 
60 	 aspartyl S cerevisiae yapsin 2 
aspartyl cathepsin D 
metaIlo- thermolysin 
65 	 metallo- peptidyl-Lys 
metallo endop eptidase 
serine 
serine 
serine 
50 
serine 
serine 
serine and 
cysteine 
variants 
55 cysteine 
cysteine 
cysteine 
Arg*, Lys*, Phe* 
Lys*, Ala*, Tyr*, Gly* 
Arg* Arg, 
Phe*Arg 
Phe*Arg 
Phe*Pro 
Lys*, Arg* 
Phe*Phe 
Phe*Lys 
Leu*Phe 
Leu*Tyr 
*Tyr, *Phe, *Leu, Me, *Val, 
Trp, and *His 
Xaa*Lys 
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cally recognized and modified by a corresponding enzyme. 
Thepeptide canbe synthesized and obtained commercially or 
the peptides can be made according to the methods described 
in Example 1. Raman active molecules such as biotin or 
Rhodamine 6G (R19) (FIG. 113) are preferably grafted 
through a short polyethyleneglycol or aminovaleric acid 
linker at the amino terminus of the peptide. 
The biomolecules may be "conjugated" (i.e., linked) to the 
nanoplasmonic resonator directly or via one or more linking 
agents. "Linking agent" as used herein refers to any com-
pound that forms a bond between the NPR and the biomol-
ecule and include e.g., a functional group, an affinity agent, or 
a stabilizing group. Suitable bonds include ionic interactions, 
covalent chemical bonds, physical forces such van der Waals 
or hydrophobic interactions, encapsulation, embedding, 
binding affinity, attraction or recognition, and various types 
of primary, secondary, tertiary linkages including but not 
limited to, peptide, ether, ester, acryl, aldehyde, ketone, acry-
loyl, thiol, carboxyl, hydroxyl, sulfhydryl and amine linkages 
or the like. 
In one embodiment, hundreds of peptides are conjugatedto 
the NPR with direct reaction between the metallic nanodisk 
of the NPR and a thiol group on the peptide. In another 
embodiment, the NPR metallic surface can also be modified 
with either amine or carboxyl group so the peptide can be 
tethered through peptide bond on the NPR surface, via reac-
tion with a heterobifunctional crosslinker that can react with 
both amine group and thiol group, or carboxyl group and thiol 
group. In a specific embodiment, an Au/S'0 2/Au/S'02 NPR 
can be functionalized with amine or carboxyl functional 
groups, and the peptides can be crosslinked via the 
crosslinker to the amine and carboxyl functional groups. Vari-
ous crosslinkers can be used for the conjugation of thiol-
activated peptides, and the surface functional groups on the 
NPRs, such as amine, carboxyl, and hydroxyl groups. 
In one preferred embodiment, the substrate peptide is teth-
ered onto the surface of an Au/S'0 2/Au NPR using a cysteine 
group at the carboxyl terminus of the peptide to attach the 
peptide to the An surface, relying on the Au-thiol reaction to 
form a covalent bond. In a preferred embodiment, multiple 
peptides are similarly conjugated to the surface of the NPR, 
each being the same or different. 
The NPR indicators described herein can utilize polypep-
tide sequences comprising one or more recognition site(s) for 
any protease(s) it is desired to detect. Proteases (proteolytic 
activity) are not only required for maintenance of normal 
cellular functions but are also central to the pathogenesis of a 
variety of human diseases. Parasitic (for example schistoso-
miasis and malaria), fungal (such as C. albicans) and viral 
infections (for example HIV, herpes and hepatitis), and also 
cancer, inflammatory, respiratory, cardiovascular and neuro-
degenerative diseases, including Alzheimer's, require pro-
teolytic activity for progress. Detection of protease presence, 
quantity, or activity is thus useful as a diagnostic/prognostic 
marker for the presence or likelihood of disease. In addition, 
detection of protease activity (or the inhibition thereof) is 
useful in screening for protease inhibitor therapeutics for the 
treatment of a number of pathologies. 
A "protease" that can be detected and/or quantified accord-
ing to the invention is an enzyme that typically hydrolyzes a 
peptide bond between a pair of amino 20 acids located in a 
polypeptide chain, also called an endoprotease. Proteases are 
typically defined by reference to the nucleophile in the cata-
lytic center of the enzyme. The most common nucleophiles 
arise from the side chains of serine, aspartic acid, and cys-
teine, resulting in families of proteases, such as serine pro-
teases (Paetzel et al. (1997) Trends Biochem. Sci. 22: 28-31), 
aspartyl proteases (Spinelli et al. (1991) Biochemie 73: 1391-
25 1396), and cysteine proteases (Altschuh et al. (1994) Prot. 
Eng. 7: 769-75, 1994). Metalloproteases usually contain a 
zinc catalytic metal ion at the catalytic site (Klimpel et al. 
5 (1994) Mol. Microbiol. 13: 1093-1100). 
A "protease recognition site" is a contiguous sequence of 
amino acids connected by peptide bonds that contains a pair 
of amino acids which is connected by a peptide bond that is 
hydrolyzed by a particular protease. Optionally, a protease 
10 recognition site can include one or more amino acids on either 
side of the peptide bond to be hydrolyzed, to which the 
catalytic site of the protease also binds (Schecter and Berger, 
(1967) Biochem. Biophys. Res. Commun. 27: 157-62), or the 
recognition site and cleavage site on the protease substrate 
15 can be two different sites that are separated by one or more 
(e.g., two to four) amino acids. 
The specific sequence of amino acids in the protease rec-
ognition site typically depends on the catalytic mechanism of 
the protease, which is defined by the nature of the functional 
20 group at the protease's active site. For example, trypsin 
hydrolyzes peptide bonds whose carbonyl function is donated 
by either a lysine or an arginine residue, regardless of the 
length or amino acid sequence of the polypeptide chain. Fac-
tor Xa, however, recognizes the specific sequence Ile-Glu- 
25 Gly-Arg and hydrolyzes peptide bonds on the C-terminal side 
of the Arg. Various preferred protease recognition sites 
include, but are not limited to protease recognition sites for 
proteases from the serine protease family, or for metallopro-
teases, or for a protease from the cysteine protease family, 
30 and/or the aspartic acid protease family, and/or the glutamic 
acid protease family. In certain embodiments preferred serine 
proteases recognition sites include, but are not limited to 
recognition sites for chymotrypsin-likeproteases, and/or sub-
tilisin-like proteases, and/or alpha/beta hydrolazes, and/or 
35 signal peptidases. In certain embodiments preferred metallo-
protease recognition sites include, but are not limited to rec-
ognition sites for metallocarboxypeptidases or metalloen-
dopeptidases. Illustrative proteases and protease recognition 
sites are shown below in Table 1. 
40 
TABLE 1 
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TABLE 1-continued 
Illustrative proteases and protease recognition sites (* indicates 
the peptide bond being hydrolyzed). 
Protease 
Family 	 Protease 	 Protease Recognition Sites 
metallo- peptidyl-Asp Xaa*Asp 
metallodndopeptidase Xaa*Glu 
Xaa*Cys 
metallo- coccolysin *Leu, *Phe, *Tyr, *Ala 
metallo- autolysin Leu-Trp-Met*Arg-Phe-Ala 
metallo- gelatinase A (MMP-2) Pro-Gln-Gly*Ile-Ala-Gly-Gln 
metallo- human neutrophil Gly-Leu- Set- Ser-Asn-Pro *Ile- 
collagenase (MMP-8) Gln-Pro 
In a specific embodiment to detect PSA, the peptide design 
will follow the amino acid sequence of the active site of 
PSA-specific peptides with serine residues and flanking 
sequences that can be recognized by PSA. In a preferred 
embodiment, the peptide contains the sequence of HSSKLQ-
LAAAC (SEQ ID NO: 1) which has been shown to have very 
high specificity for proteolytically active PSA. (See Den-
meade, S. R. et al. Specific and efficient peptide substrates for 
assaying the proteolytic activity of prostate-specific antigen. 
Cancer Res 57, 4924-4930 (1997)). It has been shown that 
HSSKLQ-L is cleaved by PSA but not by any other proteases 
in vivo in a mouse model. Thus, in another embodiment, 
multiple peptides can be generated, each having a random or 
known sequence portion, so long as each incorporates the 
highly specific sequence of HSSKLQ-LAAAC (SEQ ID 
NO: 1). 
The PSA digestion site is between the Glutamine (Q) and 
Leucine (L) residues in the peptide HSSKLQ-LAAAC (SEQ 
ID NO: 1), and the peptides are digested into 2 fragments, 
HSSKLQ and LAAAC. In the present preferred embodiment, 
the peptide is preferably tethered to the NPR surface as shown 
in FIG. 113, such that the PSA peptide is not sterically hin-
dered from the PSA enzyme and thereby optimally acces-
sible, and the Raman tag, R19, is attached to the peptide at the 
12 
Histidine. It is contemplated that an additional spacer synthe-
sized in between the peptide sequence HSSKLQ-LAAAC 
(SEQ ID NO: 1) and the NPR after the Cys (C) residue, will 
improve the presentation of PSA substrate peptide HSSKLQ 
5 on the surface and thereby increase the detection sensitivity. 
Although by doing so the distance of the Raman tag mol-
ecules could be farther from the NPR surface and resulting in 
lower Raman intensity level because the coil-like short pep-
tide structure implies large chance for the distal Raman tag 
to molecule to contact the metal surface of the NPR. In a pre-
ferred embodiment, the spacer is a packing molecule such as 
octanethiol (HS (CHz)z--CH3) and used to reduce the 
packing density of the reporting peptide on NPR surface, and 
15 thus, allows the enzyme access to the reporting peptide. 
The present approach can be used to detect the presence of 
other hydrolytic biological molecules. Thus, for example the 
peptide protease substrate can be replaced with single or 
double-stranded nucleic acids (RNA or DNA), and the indi- 
20 cator can detect and/or quantify the presence of active 
nucleases. In such instances, the nucleic acid substrate will 
typically comprise one or 30 more recognition sites for 
nucleases (e.g. restriction endonucleases). The nuclease rec-
ognition sites typically range in length from about 3 bp, 4 bp, 
5 bp, 6 bp, 7 bp, 8 bp, 9 by or 10 by to about 15 bp, 20 bp, 25 
25 bp, or 30 bp. In various embodiments the nucleic acid can 
range in length from about 3 by to about 200 bp, preferably 
from about 4 by to about 100 bp, more preferably from about 
6, 8, 10, 16, or 20 by to about 80, 60, 40, or 30 bp. 
In another embodiment, essentially any molecule that can 
so be phosphorylated by a kinase can be used as a kinase sub-
strate in the methods and compositions described herein. 
While proteins/peptides comprise the largest substrate class 
for kinases, a number of other kinase substrates are known as 
35 well. Such substrates include, but are not limited to various 
sugars (e.g., hexose, gluclose, fructose, mannose, etc.), nucle-
otides/nucleic acids, acetate, butyrate, fatty acids, sphinga-
nine, diacylglycerol, ceramide, and the like. Illustrative pro-
tein kinase substrates and the sequences is described in the 
sequence listing and Table 3. 
TABLE 3 
Illustrative protein kinase substrates 
Kinase Substrate 
SEQ ID 
NO 
cAMP-dependent protein kinase LRRASLG (Kemptide) 2 
cAMP dependent protein kinase GRTGRRNSI 3 
(PKA) 
protein kinase C (PKC) QKRPSQRSKYL 4 
protein kinase Akt/PKB RPRAATF 5 
Abl kinase EAIYAAPFAKKK 6 
5'-AMP-activated protein kinase HMRSAMSGLHLVKRR 7 
(AMPK) 
Ca2+/calmodulin-dependent KKALRRQETVDAL (Autocamtide-2) 8 
protein kinase 
cyclin-dependent kinase 2 	 (cdc2) (Ac-S)PGRRRRK 9 
cyclin-dependent kinase 2 HHASPRK 10 
(Cdk2) 
cyclin-dependent kinase 5 PKTPKKAKKL 11 
(Cdk5) 
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TABLE 3-continued 
Illustrative protein kinase substrates. 
SEQ ID 
Kinase Substrate NO 
casein kinase 1 	 (CK1) RRKDLHDDEEDEAMSITA 12 
CK2 alpha subunit or RRRDDDSDDD 13 
holoenzyme 
DYRK family protein kinases KKISGRLSPIMTEQ 14 
GSK3 alpha and beta YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE 15 
Src kinase KVEKIGEGTYGVVYK 16 
checkpoint kinases CHK1 and KKKVSRSGLYRSPSMPENLNRPR 17 
CHK2 
protein tyrosine kinases 	 (PTKs) Poly(G1u:Tyr) 4:1 is sodium salt polymer 
in phosphorylation assays. with a random amino acid distribution and 
a molar ratio of 4:1 for 
glutamic acid:tyrosine 
Thus, for example, a protein, and/or sugar, and/or complex 
carbohydrate, and/or lipid, and/or nucleic acid "substrate" 25 
can be provided coupled to one or more NPRs when the 
substrate is recognized and bound by a cognate binding part-
ner, the Raman spectrum will be changed and the interaction 
is detected. 
A typical experimental system configuration is shown in 30 
FIG. 6, comprising a microscopy system with Raman spec-
trometer used to acquire Raman scattering spectra from 
single tagged nanoplasmonic resonators. In a preferred 
embodiment, the system is comprised of inverted microscope 
equipped with a digital camera and a monochromator with a 35 
spectrograph CCD camera, a laser source and an optical lens. 
In one embodiment, Raman spectra can be measured using a 
modified inverted microscope, such as the Carl Zeiss Axio-
vert 200 (Carl Zeiss, Germany), with a 50x objective in a 
backscattering configuration. The laser wavelength can be in 40 
the visible and near infrared region. In a preferred embodi-
ment, a 785 nm semiconductor laser is used as the excitation 
source of Raman scattering, and the laser beam is focused by 
a 40x objective lens on the NPR. The 785 nm or other near 
infrared light source can assure less absorption by the bio- 45 
logical tissue and lower fluorescence background. However, 
for certain applications, lower wavelength excitation light 
might be more advantageous, and even UV light excitation 
can be used for applications. The excitation power can also be 
measured by a photometer to insure an output of —0.5 to 1.0 50 
mW. The Raman scattering light is then collected through the 
same optical pathway through a long-pass filter and analyzed 
by the spectrometer. The Raman spectrometer is preferably 
linked to a computer whereby the spectrometer can be con-
trolled and the spectra can be obtained and a spectrograph can 55 
be observed. The spectral detection can be done with ordinary 
spectral polychrometer and cooled CCD camera. The moni-
tored wavenumbers of Raman peaks range from 400 cm - ' to 
2000 cm- '. 
In one embodiment, the peptide-conjugated NPRs are 60 
incubated with a sample suspected of containing the biomol-
ecule to be detected, preferably in a closed transparent micro-
chamber. The microchamber is mounted on a 37° C. thermal 
plate on an inverted Raman microscope with darkfield illu-
mination for nanoparticle visualization. The NPRs are visu- 65 
alized using the darkfield illumination from oblique angles as 
the bright dots shown in the inset pictures in FIG. 1D. The 
excitation laser is focused on the NPRs by a microscopy 
objective lens. The SERS signal is collected by the same 
objective lens and analyzed by a spectrometer. Thepictures in 
FIG. 1D show the —0.8 mW excitation laser spot focusing on 
a field of NPRs. 
The real-time detection of enzymatic reactions can occur 
within 30 minutes. However, the incubation and detection can 
be as short as 1 to 5 minutes and as long as 24 hours, or longer, 
if the application needs longer incubation time biologically. 
After initial centrifugal fractionation, the soluble content in 
biological sample can be directly incubated with the NPRs or 
the NPR array. In one embodiment, to specifically inhibit the 
protease-mediated proteolysis of the conjugated peptides, 
protease inhibitors are introduced prior to the addition of the 
protease. For example, the peptide digestion by PSA is more 
than 90% suppressed after the addition of inhibitors given the 
same experimental conditions. 
In various embodiments the enzyme presence, and/or con-
centration, and/or activity is determined in a biological 
sample. The biological sample can include essentially any 
biomaterial that it is desired to assay. Such biomaterials 
include, but are not limited to biofluids such as blood or blood 
fractions, lymph, cerebrospinal fluid, seminal fluid, urine, 
oral fluid and the like, tissue samples, cell samples, tissue or 
organ biopsies or aspirates, histological specimens, and the 
like. 
One typical experimental detection scheme for enzyme 
presence, concentration and activity is shown in FIG. 5. In the 
method, a solution or sample is provided to a peptide-conju-
gated SERS NPR or NPR array. Before the enzymatic reac-
tion, the SERS spectrum of a peptide-conjugated NPR con-
tains the characteristic peaks from the Raman tag molecules, 
the peptides, and the nanoplasmonic resonator. The enzy-
matic reaction by the enzyme should modify the peptide at a 
predetermined modification site. For example, during the 
digestion reaction by PSA, the peptide HSSKLQ-L is cleaved 
between the Q and L residues, here denoted by a dashed line. 
The SERS spectra of the artificial peptides change after cleav-
age by the protease because the cleavage fragment containing 
the Raman tag molecules diffuses away from the NPR sur-
face, while the other fragment remains on the NPR surface. 
The characteristic SERS peaks of the molecular moieties with 
the Raman active tag disappear due to the diffusive disloca-
tion of the tag molecules from the NPR surface into the 
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solution after peptide digestion; therefore the existence and 
concentration of the proteolytically active PSA in solution 
can be probed by monitoring the SERS spectra of the peptide-
conjugated NPRs. The Raman scattering signal of the 
attached peptide is then amplified by the NPR and detected by 
a microscopy system as described comprising a Raman spec-
trometer to acquire Raman scattering spectra from single or 
arrayed NPRs. For example, as shown in FIG. lg, the mea-
sured resonance peak of NPRs-peptide-R19 conjugates 
closely matches laser excitation wavelength at 532 mn and 
thus, maximizes the enhancement of Raman scattering. As 
shown in FIG. lh, NPR-based SERS substrate exhibits repro-
ducible Raman spectrum with consistent enhancement factor 
at same order of magnitude. The variation of experimentally 
measured the SERS intensities obtained from 6 different NPR 
array are below 25% and it can be easily normalized in the 
experiment. 
The reaction dynamics can be monitored by time-resolved 
SERS spectra acquisitions. In one embodiment, the assay can 
be performed by exposing the biomolecule-conjugated NPR 
array to biological fluidic samples and the subsequent time-
dependent R19 Raman spectra change is recorded at an inter-
val of about one minute and an integration time of about 30 
seconds. The Raman peak at 1316 cm - ' of SERS label mol-
ecule (R19) can be monitored as the primary signature peak, 
while the other signature peaks such as 1456 cm - ', 1526 
cm- ', and 1597 cm- ' peaks, may be also monitored as addi-
tional references (see FIG. 2). The time-resolved spectral 
measurement in the presence of an enzyme can be plotted as 
in FIG. 2c. The SERS intensities are proportional to any 
remaining biomolecules on the NPR surface that have not 
been acted on by the enzyme, thus making the normalized 
SERS intensity change a direct indicator of enzyme activity. 
Despite the variation in the initial intensity of different 
Raman signature peaks, the normalized data all converge into 
the same curve, indicating the normalized SERS intensity 
change is a reliable measure to quantitatively determine the 
peptide being profiled or detected. 
For example, as shown in FIG. 2c, before enzyme addition, 
the peptide-conjugated NPR shows steady intensities for all 
the peaks over a 10 minute period. However, upon addition of 
an enzyme, a significant decrease in each Raman peak is 
observed in the first 10-12 minutes, indicating that the 
enzyme is active and was able to cleave the peptides on the 
NPR. At the endpoint of 30 minutes, the decrease of the 
Raman signal reaches a plateau at PSA concentration of 6 nM 
while at lower concentration level (—pM), the signal contin-
ues to decrease at a much lower rate. Another serine protease, 
Granzyme B, was selected as a negative control (FIG. 2b-c). 
Within 50 minutes of recording, no substantial changes in 
SERS intensity was observed, even at concentrations up to 1 
µM. This result demonstrates that the decrease of Raman 
signal in the PSA assay was based on a genuine enzymatic 
process, rather than a non-specific hydrolysis reaction or due 
to the displacement of the peptide from the surface by other 
components in the buffer 
In a preferred embodiment, the time-lapse intensities of the 
Raman peak of the Raman active tag in the NPR SERS probe 
in the digestion reaction is obtained with the protease, the 
protease with inhibitor, and a negative control, respectively. 
All the peak intensity values are normalized to the internal 
control peak (e.g., In FIG. lg, the peak intensity measured for 
the R19-peptide and NPR is 532 cm - ') and the initial peak 
intensity at the wavenumber of either the positive or negative 
control. In one embodiment, the negative control is a NPR-
peptide hybrid, in which the peptide is not a substrate of the 
protease(s) of interest and would not be cleaved by the pro- 
16 
tease(s) being studied. The results should indicate that the 
peptides are efficiently and specifically cleaved by PSA by the 
gradual disappearance of the peak intensity of the Raman 
active tag. 
5 	 The NPR particle serves as the Raman signal amplifier and 
the detected Raman signal comes from all the peptides teth-
ered on the surface of the NPR particle. In one embodiment, 
at least 100 peptide molecules are attached per NPR. Even if 
this number of peptides is attached, it is contemplated that the 
10 NPR surface with the highest SERS signal is not fully taken 
advantage of, if a small percentage of the peptides are 
attached to the region that provides the greatest enhancement 
in electromagnetic field (FIG. 1Q. The numerical simulation 
15 (FIG. lc) indicates the amplitude of the local electric field can 
be enhanced by close to 20 dB (100 fold) especially around 
the edge of the nanodisk. Due to the fourth power relation 
between the electric field amplitude and the Raman enhance-
ment factor, the peptide Raman signal could be amplified 
20 several fold (e.g. 10 $) by the NPR. 
Furthermore, because tens to hundreds of peptides are used 
in the conjugation reaction for each NPR on average, the 
disappearance of the characteristic Raman peaks from the tag 
molecules is not abrupt. Since most of the enhanced field is 
25 concentrated around the tip area, which accounts for —'/6 of 
total area of the NPR, the actual molecule number contribut-
ing to the Raman scattering signal in this high enhancement 
area is less than 20, even if assuming the conjugation effi-
ciency is 100% (FIG. 1d). 
30 	 In a preferred embodiment, a positive control is used. For 
example, in one embodiment, the intensities of the Raman 
peak for apositive control as a function of PSA digestion time 
for various PSA concentrations are obtained before detection 
35 of PSA presence or activity in a sample. The typical SERS 
spectra of the peptide-conjugated NPRs with positive con-
trols biotin and R19 Raman tag molecules are shown in FIGS. 
3a and 3b, respectively. By comparing the SERS spectra 
before and 2 hours after the peptide digestion experiments, 
40 the Raman peaks from the NPR core (e.g., polystyrene core, 
e.g. 1003 cm- ') remain constant, and thus can also serve as an 
internal control. The digestion rate is related to the PSA 
concentration and PSA activity is typically observed in 30 
min for a concentration 1 nM (with —50% reduction in biotin 
45 signal intensity, data not shown). Some Raman peaks from 
the partial amino acid chain remaining on the NPR surface 
after digestion may still appear in the spectra, although the 
peak positions have slight changes and the peak intensities 
decrease due to possible conformational changes upon pep- 
50 tide cleavage. 
In another embodiment, a negative control is run to show 
that the peptides are specifically cleaved by protease present 
in the sample. Example 1 shows the specificity of the conju-
gated peptides to PSA using other serine proteases such as 
55 Granzyme B, which can serve as a negative control. FIGS. 2B 
and 2C shows the time-lapse SERS spectra of NPRs with R19 
tag molecules in the two control experiments with the PSA 
inhibitor and the serine protease Granzyme B, which has 
orthogonal substrate specificity to PSA, respectively. In the 
60 control experiment of peptide digestion by 420 nM 
Granzyme B, the reaction rate showed no statistically signifi-
cant difference from the inhibitor-treated reaction. The 
inability for Granzyme B to cleave the peptide is also 
expected as PSA has been shown to be the only protease for 
65 the HSSKLQ-LAAAC sequence in vivo. 
In a preferred embodiment, this peptide-conjugated NPR 
can be used as a specific screening tool to provide information 
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on the concentration and proteolytic activity of the cancer 	 cal fiber from a 150 W Xe white light source. The light was 
biomarker PSA in biological samples obtained from patients 	 delivered through a right angle prism at an angle resulting in 
in a clinical setting. 	 total internal reflection (TIR), and the scattered light was 
In another embodiment, the peptide-conjugated NPR can 	 collected with a JY (550 grating) spectrometer system (Jobin 
be used as a specific screening tool to provide information on 5 Yvon). See FIG. 5B. For the SERS experiment, SERS spectra 
the concentration and enzymatic activity of a biomarker, 	 were measured using a modified Zeiss inverted confocal 
enzyme, kinase or other protease in biological samples 	 microscope with a 20x objective in a backscattering geom- 
obtained from patients in a clinical setting. 	 etry. An argon laser operating at 514 mn (attenuated to —10 
It is contemplated that one application of the present 	 mW) was coupled into the microscope, and the appropriate 
probes is the incorporation of an NPR particle into a microf-  io interference filters and holographic notch filter (Kaiser) were 
luidic device which can automate and facilitate sample deliv- 	 placed in the beam path to remove the unwanted laser lines. 
ery and washing process. The NPR particles can be also 	 The output light path was coupled into the same spectroscope 
delivered in real-time or immobilized in the device. 	 as the scattering spectra measurement. See FIG. 5A. 
In another embodiment, NPRs can be spatially arranged in 	 In the measurements, the polarization of the incident 
a microarray format to achieve multiplexed measurements 15 E-field is parallel to the TNPR long axis. FIG. 2a depicts the 
with broad applications, by measuring all known proteases in 	 scattering spectra of an individual TNPR and a capped TNPR 
unprocessed biological samples without complex sample 	 with resonant peaks at 516 and 536 mu, respectively. The 
processing and purification steps. The multiplexity of the 	 sandwiched S'02 layer works as a tunable coupling factor for 
substrate peptide spatially can be achieved with a microar- 	 the plasmon resonant frequency, and the top S'0 2 layer works 
rayer with industry standard protocols, when combined with 20 as a cover layer to prevent the molecules from self-assem- 
NPR nanoarray clusters arranged in microarray format. Even 	 bling on top of the metal surface. The observed red-shift of the 
if each of the 500+ proteases are cross-interrogated by 10 	 resonance spectrum of the capped TNPR is due to the pres- 
different substrate peptides, the array still has an easily man- 	 ence of the S'0 2 layer, which locally increases the refractive 
ageable feature number of less than ten thousand. 	 index. 17 p-Mercaptoaniline (pMA), a commonly used 
25 Raman dye, was selected in this study. The low fluorescence 
EXAMPLE 1 	 emission background makes it a good candidate for qualita- 
tive analysis of the Raman signal. 
Raman Enhancement Factor of a Single Tunable 	 To ensure maximum coverage of the pMA monolayer on 
Nanoplasmonic Resonator (TNPR) 	 the TNPR surface, the substrates were incubated in a 100 iM 
30 pMA solution for more than 24 h. After repeatedly rinsing 
The TNPRs were patterned on quartz substrates (HOYA 	 with DI water to remove unwanted pMA adsorbed on the 
Co.) by electron beam lithography (EBL) (Leica Microsys- 	 substrate and S'0 2 capping layer, the substrate was thor- 
tems Nanowriter Series EBL 100). A 30 mn thick indium tin 	 oughly dried with N2 gas. The spectra measurements indicate 
oxide (ITO) layer was first sputtered on the substrate to pre- 	 the scattering peak positions of pMA-coated capped and non- 
vent charging effects during the EBL process. Poly(methyl 35 capped TNPRs were shifted to 534 and 550 mu, respectively 
methacrylate) (100 nm thick, MicroChem. Corp. PMMA) 	 (FIG. 2b). The results indicate that the presence of pMA in the 
films, spincoated on the ITO-quartz glass, were used as a 	 vicinity of the TNPR causes a red-shift of the resonance 
positive photoresist. After exposure, the patterns were devel- 	 spectrum, equaling 18 mn for noncapped TNPRs and 14 mn 
oped using a 1:3 ratio of a methyl isobutyl ketone and isopro- 	 for capped TNPRs. This observation shows that pMA on top 
pyl alcohol mixture, followed by multilayer electron beam 40 of an uncapped TNPR does not lead to a significant shift 
evaporation of silver and oxide and standard lift-off proce- 	 (below 5 mu) and the surface plasmon modes in the TNPR 
dures. We fabricated three-layered Ag/S'0 2/Ag and four-lay- 	 may be more sensitive to the local refractive index change on 
ered Ag/S'0 2/Ag/S'02 TNPRs on the same substrate (we 	 the sidewall (in the direction of the excitation electric field) 
refer to the four-layered TNPR as the capped TNPR in this 	 than on the top surface. Numerical simulations are more 
example), with each silver and S'0 2 layer thickness fixed at 45 desirable to obtain a qualitative explanation of the peak shift 
20 and 5 mu, respectively. A shadow mask was inserted over 	 for different sample configurations. It should be noted that 
the three-layered TNPRs during deposition of the additional 	 these peak shifts suggest TNPRs can also serve as molecule/ 
5 nm S'02 capping layer to prevent deposition on the three- 	 bio sensors to monitor local refractive index changes. 
layered TNPRs. The samples were measured by scanning 	 The SERS EF for the TNPRs was evaluated by directly 
electron microscopy and atomic force microscopy to deter-  50 comparing the SERS intensity obtained from TNPRs with 
mine their sizes, shapes, and thicknesses. The SiO2 layer 	 unenhanced molecules using the expression EF) (RS T'PRl 
sandwiched between the metallic layers can be used to tune 	 RS'f'' ')([reference]/[TNPR]). RS' and RS" f —"" are 
the surface plasmon resonance frequency by adjusting its 	 the measured SERS intensity of the TNPRs and normal 
thickness. The EF can be maximized by matching the surface 	 Raman standard sample, respectively. [TNPR] and [refer- 
plasmon resonance to the pump laser frequency. Under an 55 ence] are the estimated number of molecules in the experi- 
optical microscope, these particles, as shown in FIG. ld, are 	 ments. A saturated pMA monolayer coverage of 0.39 nm2 per 
distinctively visible due to the strong scattering of light at 	 molecule is used to estimate the number of molecules on a 
resonant wavelengths. Scanning electron microscopy (SEM) 	 TNPR surface. 18 Assuming that an individual TNPR is a 
images (FIG. le) show that the TNPRs are slightly elongated 	 cylindrical ellipsoid particle, the maximum number of pMA 
with a long axis and short axis of 117 and 81 mu, respectively. 60 molecules that can self-assemble is —5.1 x10 4 . A 0.1 mL neat 
Atomic force microscopy (AFM) measurement (FIG. lf) con- 	 liquid pMA (1.06 g/cm3) droplet on a quartz substrate with a 
firms that the height difference between capped TNPRs and 
	
known detection volume from a 20x microscope objective 
noncapped TNPRs is 5 mu, which matches the thickness of 	 was used to estimate the number of molecules for the refer- 
the SiO2 capping layer. Conducting AFM was used to ensure 	 ence sample, giving —4.5x10 13 pMA molecules. We took 
a good S'0 2 layer coverage between the metal disks. 	 65 SERS spectra on a single TNPR at 10 different locations with 
Scattering spectra were obtained by illuminating the 	 exactly the same exposure time and individual Raman spec- 
TNPRs with collimated light delivered by a multimode opti- 	 tra, which are depicted in FIG. 3. Remarkably, the intensities 
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of the measured Raman spectra are very constant, showing 	 size variation effects, often associated with chemical synthe- 
	
that fabrication repeatability of particles shapes is very reli- 	 sis or self-assembly of colloidal nanoparticles. Thus, it offers 
	
able. Especially, the signal strengths of the 1590 and 1077 	 a unique advantage for the development of integrated bio- 
	
cm-1 ring modes of pMA were monitored. By looking care- 	 sensing devices. 
fully at the raw data, we found that the intensity of these two 5 
	
modes is very constant among measurements. The maximum 	 EXAMPLE 2 
SERS EF from an individual TNPR reached —(3.4±0.3)x10 10 
	
and (2.9±0.3)x10 10 at 1077 and 1590 cm-1, respectively, and 	 Protease-Specific Substrate Peptide Conjugated Nprs 
	
the errorbars were obtained from sample-to-sample variation 	 for Real-Time Protease Detection and Measurement 
of Raman scattering intensity. It should be noted that the 10 
	
possible error in estimating the surface coverage of pMA and 
	
In this work, NPRs (FIG. la) were conjugated with a PSA 
	
the volume illuminated by the microscope objective obvi- 	 protease-specific substrate peptide, which has the sequence 
	
ously affects the precision in calculating the SERS EF. To 	 R19-HSSKLQLAAAC (SEQ ID NO: 1) (S. R. Denmeade, C. 
	
provide a trustworthy estimation of the SERS EF for a TNPR, 	 M. Jakobsen, S. Janssen et al., JNatl Cancerinst 95 (13), 990 
we are performing the calculation in the most conservative 15 (2003); S. R. Denmeade, W. Lou, J. Lovgren et al., Cancer 
	
manner. The SERS EF was determined by assuming maxi- 	 Res 57 (21), 4924 (1997)), with the SERS molecule 
	
mum pMA coverage over the entire TNPR metal surface and 
	
Rhodamine 19 (R19) at the N-terminus and cysteine at the 
	
with the smallest volume being illuminated by microscope 	 C-terminus (FIG. lb). The peptide has been identified as a 
	
objectives. The reported value is in fact representing the lower 	 highly specific peptides that can be cleaved by paPSA in vivo 
bound of the SERS EF, and the actual EF can be even higher. 20 in xenografts models (S. R. Denmeade, C. M. Jakobsen, S. 
	
We also measured the Raman spectra on S'0 2 -capped 
	
Janssen et al., J Natl Cancer Inst 95 (13), 990 (2003)) and 
	
TNPRs to isolate the SERS contribution from the sidewall of 
	
human samples (P. Wu, U. H. Stenman, M. Pakkala et al., 
	
the capped TNPRs. We assumed that there are no pMA mol- 	 Prostate 58 (4), 345 (2004); P. Wu, L. Zhu, U. H. Stenman et 
	
ecules self-assembled on the SiO2 layer after copious DI 	 al., Clin Chem 50 (1), 125 (2004)). The paPSA cleaves the 
water rinsing. The ratio of pMA molecules self-assembled on 25 peptide, leading to the release of the RI9 moiety (FIG.lc)and 
	
the exposed metal surface of the TNPR to that of the capped 	 a subsequent decrease in the Raman scattering intensity in a 
	
TNPR was assumed to be the same as the area ratio, which is 	 dose- and time-dependent manner, and the PSA protease 
	
about 1.6. The maximum measured SERS EF intensity on the 	 activity can be accurately quantified. It has been theoretically 
	
capped TNPR reaches (6.1±0.3)x10' 0 and (4.6±0.3)x10' 0 for 	 estimated that SERS enhancement is strongly localized to the 
the 1077 and 1590 cm- ' ring modes, respectively. The relative 30 vicinity of nanoparticle resonator surface (5-10 mu), which 
	
SERS intensity ratio for a TNPR to a capped TNPR is 	 effectively eliminates the assay background noise from the 
	
approximately 1.3. This is an interesting observation, since 	 Raman scattering substance in the surrounding fluids, or the 
	
the SERS EF ratio between the capped TNPR and the TNPR 
	
R19 moieties that diffuse into the solution after protease 
	
is not proportional to the number of molecules assembled on 	 cleavage. Because of this unique property, the assay can be 
the exposed metal surface. 	 35 performed in a simplified one-step format with no additional 
	
To understand these experimental results, we performed 	 washing step required. 
	
several numerical calculations. We applied the discrete dipole 	 Under an optical microscope, the NPR arrays were dis- 
	
approximation (DDA) method to compute the near field dis- 	 tinctly visible due to the strong scattering of light at their 
	
tribution of the E-field surrounding the TNPR. FIG. 4 shows 	 resonant wavelength (FIG. ld). The magnified views of NPR 
the calculated E-field amplitude distribution at the sidewall 4o arrays that measured by Scanning Electron Microscope 
	
and top surface of a TNPR with the geometrical parameters 	 (SEM) and Atomic Force Microscope (AFM) are showing in 
	
corresponding to the SEM and AFM measurements. The per- 	 FIGS. le and lf. The optical properties of the NPR were 
	
mittivity of Ag is taken from the literature for bulk Ag mate- 	 characterized by illuminating the NPRs with collimated light 
	
rial, and the permittivity of S'0 2 is set to 2.13. The substrate, 	 delivered by a multimode optical fiber from a 150 W Xenon 
which has significant effects on the plasmon resonance, is 45 lamp (Thermo Oriel) and collecting the extinction spectra 
	
taken into account by embedding the particle in a homoge- 	 using a grating spectrometer (Triax 550, Jobin Yvon) with 
	
neous medium with a refractive index of 1.4, which is the 	 matched liquid nitrogen cooled CCD detector (CCD-3500, 
	
averaged refractive index of air and ITO.26 FIG. 6c clearly 	 Jobin Yvon) (Durant S. Su K, Steel M. J., Xiong Y. Sun C., 
	
shows an angular dipole-like E-field distribution where stron- 	 Zhang X, Journal of Physical Chemistry B 110 (9), 3964 
ger fields are localized along the incident polarization direc-  50 (2006)). The S'0 2 layer, sandwiched between the Ag layers, 
	
tion 0-0 (along the TNPR long axis). The z dependence of the 	 enable precisely tuning of NPR resonance. As shown in FIG. 
	
field shows that the strong local fields are mainly distributed 
	
lg, the measured resonance peak of NPRs-peptide-R19 con- 
	
close to the Ag/S'0 2, Ag/air, and Ag/ITO interfaces. FIG. 6b 
	 jugates closely matches laser excitation wavelength at 532 
	
shows that the stronger fields or "hotter spots" are mainly 	 mu, and thus, maximizes the enhancement of Raman scatter- 
located close to the edge of the ellipse around the direction of 55 ing. For the SERS experiments, Raman spectra were mea- 
the incident polarization. 	 sured using a modified inverted microscope (Axiovert 200, 
	
In summary, we studied the SERS EF of TNPRs. The 	 Zeiss) with a 50x objective in a backscattering configuration. 
	
observed SERS EF of a single TNPR can be as large as 	 As shown in FIG. lh, the NPR-based SERS substrate exhibits 
	
6.1 x10 10 when the plasmon resonance is tuned to the pump 	 reproducible Raman spectrum with consistent enhancement 
laser frequency, which is among the highest reported to date. 60 factor at the same order of magnitude. The variation of experi- 
	
We developed a novel technique that forces the molecules to 	 mentally measured SERS intensities obtained from 6 differ- 
	
be assembled on the sidewall of the resonator where the field 	 ent SERS NPR array are below 25% and it can be normalized 
	
is strongest, giving an accurate measurement of the Raman 	 in the experiment. 
	
enhancement factor. The experimental results agree well with 
	
The assay was performed by exposing the NPR-peptide 
numerical calculations of the TNPR. Nanofabrication enables 65 nanosensor to the fluidic samples and the subsequent time- 
	
precise dimension control and accurate placement of the 	 dependent R19 Raman spectra change was recorded at an 
	
TNPRs, eliminating the issues resulting from aggregation and 
	
interval of one minute and an integration time of 30 seconds. 
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The Raman 1316 cm- ' ring breathing mode from the PSA 
peptide was monitored as the primary signature peak in this 
study, while the 1456 cm- ', 1526 cm- ', and 1597 cm- 'peaks 
were also monitored as additional references (FIG. 2). The 
time-resolved spectral measurement in the presence of PSA 5 
(FIG. 2a) is plotted in FIG. 2c. Considering that the SERS 
intensities are proportional to the remaining R19 on the NPR 
surface, the normalized SERS intensity change is a direct 
indicator of PSA activity. Despite the variation in the initial 
intensity of different Raman signature peaks, the normalized io 
data all converged into the same curve, indicating the normal-
ized SERS intensity change is a reliable measure to quantita-
tively determine the substrate peptide being cleaved. As 
shown in FIG. 2c, before PSA addition, the NPR nanosensor 
showed steady intensities for all the peaks over a 10 minute 15 
period. However, upon addition of PSA, a significant 
decrease in each Raman peak is observed in the first 10-12 
minutes, indicating that the PSA protease was able to cleave 
the peptides on the NPR. The decrease of the Raman signal 
then reaches a plateau by 30 minutes. Another serine pro- 20 
tease, Granzyme B, was selected as a negative control (FIG. 
2b-c). Within 50 minutes of recording, no substantial changes 
in SERS intensity was observed, even at concentrations up to 
1 µM. This result demonstrates that the decrease of Raman 
signal in the PSA assay was based on a genuine enzymatic 25 
process, rather than a non-specific hydrolysis reaction or due 
to the displacement of the peptide from the surface by other 
components in the buffer. 
The sensitivity of the NPR nanosensor was evaluated by 
measuring SERS intensity change of set of sample with PSA 30 
enzyme concentration ranging from 6 nM to 6 pM. The abso-
lute value of normalized SERS intensity change is shown in 
FIG. 3a. As expected, the rate of decrease in the Raman signal 
was proportional to the concentration of PSA, which is 
explained by a reduced rate of peptide cleavage when the PSA 35 
concentrations decreased. The proteolytic activity eventually 
reaches an equilibrium stage at 30 minutes as indicated by 
each Raman signal reaching a plateau. The absolute value of 
normalized decrease in SERS intensity versus various con-
centrations, after 30 minutes of enzyme addition, is plotted in 40 
FIG. 3b. The dynamic range for detection, in the current assay 
setup, was from 6 pM to 6 nM. PSA concentration higher than 
6 nM does not exhibit a distinct difference with the given 
detection time. As shown in FIG. 3c, the monitored Raman 
peak intensity exhibits distinguishable decay characteristics 45 
at different PSA concentrations during the initial 4 minutes of 
sampling. Thus, by fitting the decaying rate, reliable assays 
can possibly be accomplished in 4 minutes. 
In addition to protease activity measurements of purified 
PSA, measurements for PSA protease activity in extracellular 50 
fluid (ECF) from live cell culture was performed (FIG. 3d). It 
is well known that LNCaP cells secrete PSA and have 
recently been used in xenografts to evaluate in vivo PSA 
concentration (S. R. Denmeade, C. M. Jakobsen, S. Janssen et 
al., JNatl Cancer lnst95 (13), 990 (2003)). For comparison, 55 
a K562 cell line, which does not secrete PSA into the ECF, 
was used as a negative control. LNCaP ECF showed a sig-
nificant change in SERS signal, while K562 exhibits very low 
PSA enzymatic activity (FIG. 3d). By correlating the normal-
ized decrease in Raman signal with FIG. 3b, it was deter- 60 
mined that the LNCaP media had an elevated amount of 
paPSA concentration (FIG. 3d). 
Compared with fluorescence-based assay, the NPR-based 
method offers several advantages. Strongly localized Raman 
enhancement can substantially amplify the signal and also 65 
effectively reduce background noise. Therefore, it allows 
one-step and label free detection of protease activity with  
22 
sensitivity at 6 pM, and dynamic range of 3 orders of magni-
tude. It should note PSA is considered a weak protease and 
other proteases would allow even better sensitivity. Second, it 
allows accurate measurement with very small sample vol-
ume. Indeed, we estimate PSA protease activity from single 
cells can be measured accurately (See below). Third, fabri-
cated using well established nano-lithography process, NPR-
based method is highly reproducible and thus, allowing quan-
titative assessment of protease activity. 
Methods 
NPR Fabrication 
The NPR was patterned on quartz substrates (HOYA 
Corp.) by electron beam lithography (EBL) (Nanowriter 
Series EBL 100, Leica Microsystems). A 30 mu thick indium-
tin-oxide (ITO) under-layer was sputtered on the substrate to 
prevent charging effects during the EBL process. 100 mu-
thick polymathylmethacrylate (PMMA, MicroChem. Corp.) 
films spin-coated on the ITO-quartz glass was used as a 
positive photoresist. After exposure, the patterns were devel-
oped using a 1:3 ratio of MIBK and IPA mixture followed by 
multilayer deposition of metal and dielectric materials using 
electron beam evaporation (Mark 40, CHA) and standard 
lift-off procedures. We fabricated three layered Ag/S'0 2/Ag 
NPR arrays with each silver and S'0 2 layer thickness equal to 
25 nm and 5 mu, respectively. The geometry of the fabricated 
NPR was examined by atomic force microscopy, and the total 
thickness of the NPR is confirmed to be 55 mu. 
Device Design and Characterization 
Micro-region SERS measurements are performed on an 
inverted optical microscope (Axiovert 200, Zeiss) with 
matched high resolution grating spectrameter (Triax 550, 
Tobin Yvon). Instrumental set-up is shown in FIGS. 5A and 
5B. To excite the particles plasmons, the Nanoplasmonic 
Resonators (NPRs) were illuminated with a collimated laser 
beam (Frequency doubling YAG laser, 532 mu) through a 
right angle prism at an angle resulting in a total internal 
reflection (TIR) configuration. An evanescent electromag-
netic wave is generated and used to excite the particle plas-
mons. The samples are attached to the bottom of the prism by 
applying index matching oil between the sample substrate 
and the prism. Such sample configuration effectively elimi-
nates all stray scattering light due to surface defects and dust 
particles, leading to significantly reduced background signal. 
The excited collective electron oscillations within the par-
ticles then radiate electromagnetic waves of the same fre-
quency into the far field, whereby the collection and spectral 
measurement takes place. The scattered light from the NPRs 
is then collected by a 50x long working distance objective. A 
holographic notch filter (532 mu, Kaiser Optical System) was 
placed in the beam path in order to remove the illuminating 
beam. The emerging light is then imaged onto the entrance slit 
of the grating spectrometer system with a liquid Nitrogen 
cooled charge coupled device (CCD) camera (CCD-3500, 
JobinYvon) for spectrum analysis. 
The extinction spectrum measurement was performed in a 
similar configuration. In this measurement, 150 W Xenon 
white light source has been used as the illumination source 
and the collimated light was delivered through an optical fiber 
bundle. 
For the SERS experiments, Raman spectra were measured 
using a modified inverted microscope (Axiovert 200, Zeiss) 
with a 50x objective in a backscattering configuration. Base-
line subtraction was applied to remove the fluorescence back-
ground of the measured spectra. The spectra were then 
smoothed in Matlab using the Savitsky-Golay method with a 
second-order polynomial and window size of 9. To correct the 
possible influence due to the fluctuation of illumination inten- 
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sity, frequency dependence of Raman scattering, and the 
variation of initial packing density of the report molecules, 
the change in SERS intensity was normalized to the average 
intensity before protease addition. The normalized SERS 
intensity change is defined as 
A1-/1,-IQ//I0 
where Io is the average SERS intensity before the addition of 
the protease and I, is the SERS intensity measured at the given 
time t. 
To estimate the detection volume of the NPR array, the 
diffusion length is first calculated as L D-VDt-0.5 mm where 
D is estimated as 1 x10 -6  cm2/s and t is 1800s. The un-nor-
malized detection volume is then determined as V=(L A +LD)2 
LD-1x10-' L where LA is the length of the NPR array (15 
µm). This volume must be normalized due to the fact that the 
molecules have an equal likelihood to diffusion in any direc-
tion. The likelihood of these molecules coming in contact 
with the NPR array can be estimated based on the surface area 
of the array and the total surface area available for diffusion. 
This probability of molecules can diffuse to the NPR array is 
then given by: 
z 
Wier 
 = 6 l 
- 1.5 x 10-4 
D 
assuming the NPR array surface area of the array is much 
smaller than the available diffusion surface area. The total 
sampling volume is then calculated as Viet WD,V-15 pL. 
Peptide Synthesis 
R6G-Ava-HSSKLQLAAAC-NH 2 (SEQ ID NO: 1). (2). 
401 mg (0.277 mmol) of Rink Amide AM polystyrene resin 
(loading 0.69 mmol/g) was added to a 12 mL fitted syringe 
and swollen with NMP (4 mL). The Fmoc protecting group 
was removed by treatment with 1:2:2 piperidine/NMP/ 
CHzClz solution (3 mL) for 30 min, and the resin was filtered 
and washed with NMP (3x3 mL) and CH zClz (3x3 mL). To 
load the a-amino acid residues, the resin was subjected to 
repeated cycles of coupling conditions (method A or method 
B), followed by washing (5x3 mL NMP, 50 mL CH zClz), 
Fmoc deprotection [treatment with 1:2:2 piperidine/NMP/ 
CHzClz solution (3 mL) for 30 min], and washing again with 
NMP (50 mL) and CHzClz (5x3 mL). The first a-amino acid 
residue was loaded by addition of a preformed solution of 
Fmoc-Cys(Trt)-OH (1.17 g, 2.00 mmol), PyBOP (1.04 g, 
2.00 mmol), and HOBt (270 mg, 2.00 mmol) in 1:1 NMP/ 
CHzClz (2 mL) onto the resin and the resulting slurry was 
stirred for 5 min on a wrist-action shaker, followed by addi-
tion of i-PrzEtN (0.55 mL, 4.0 mmol). The reaction was 
allowed to proceed for 5 h. The resin was then filtered, washed 
(50 mL NMP, 50 mL CHzClz), and dried under high 
vacuum. The loading of Cys was determined to be 0.60 
mmol/g (78% yield). Successive couplings were achieved 
either by method A or method B. Method A consists of addi-
tion a preformed solution of Fmoc-protected amino acid 
[Fmoc-Cys(Trt)-OH (1.17 g, 2.00 mmol), Fmoc-Ala-OH 
(622 mg, 2.00 mmol), Fmoc-Leu-OH (707 mg, 2.00 mmol), 
Fmoc-Gln(Trt)-OH (1.22 g, 2.00 mmol), Fmoc-Ser(tBu)-OH 
(767 mg, 2.00 mmol), and Fmoc-His(Trt)-OH (1.24 g, 2.00 
mmol)], PyBOP (1.04 g, 2.00 mmol), and HOBt (270 mg, 
2.00 mmol) in NMP/CHzClz (1:1, 2 mL), followed by addi-
tion of i-PrzEtN (0.55 mL, 4.0 mmol). The reactions were 
allowed to proceed for at least 4 h. Method B consists of 
subjection of the resin to a 0.4 M solution of the suitably 
protected acid [Fmoc-Lys(Boc)-OH (375 mg)], which had 
been pre-activated by incubation with DIC (130 µL, 0.84 
mmol) and HOBt (108 mg, 0.800 mmol) in DMF (2 mL) for 
10 min. The coupling was allowed to proceed for 4 h. After 
each coupling the resin was filtered and washed (NMP: 50 
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mL, CH2C12 : 5x3 mL), followed by removal of the Fmoc 
protecting group. After coupling and deprotection of the final 
a-amino acid residue, theAva linker was added by subjection 
of the resin to a 0.4 M solution of Fmoc-S-Ava-OH (272 mg, 
5 0.800 mmol) which had been pre-activated by incubation 
with DIC (120 µL, 0.80 mmol) and HOBt (108 mg, 0.800 
mmol) in N-methylpyrrolydinone (1 mL) for 10 min. The 
coupling was allowed to proceed overnight. The resin was 
filtered and washed (50 mL NMP, 5x3 mL CH zClz), the 
10 Fmoc protecting group was removed, and the resin washed 
again. The rhodamine group was incorporated by adding a 0.4 
M solution of rhodamine 19 (412 mg, 0.8 mmol), which had 
been pre-activated by incubation with DIC (130 µL, 0.84 
mmol) and HOBt (108 mg, 0.800 mmol) in NMP (2 mL) for 
15 10 min. The reaction was allowed to proceed for 6 h, the 
coupling procedure was repeated once more and the reaction 
was allowed to proceed overnight. The substrate was cleaved 
from the resin by incubation with a solution of 94:2:2:2 TFA/ 
triisopropylsilane/H 20/ethanedithiol (3 mL) for 2 h, purified 
using preparatory C18 reverse-phase HPLC (CH,CN/H z0- 
20 0.1% TFA, 5-95% for 50 min, 20 mL/min, 220/254/280 nm 
detection for 100 min, tR=24.3 min), and lyophilized. MS 
(MALDI), m/z calcd for C7,H116N19017S:  1622.85. Found: 
m/z 1623.90. 
Peptide Conjugation to NPR 
25 	 The peptide attaches to the NPR via the thiol group on 
cysteine. The PSA substrate peptides mixed with octanethiol 
at a 1:3 ratio were incubated for 24 hours to ensure a well-
ordered self-assembled monolayer (SAM) on the NPR metal-
lic surface. Octanethiol, with a SAM chain length of 1-2 nun, 
30 was used as packing material to manage the distance among 
the PSA substrate peptides and help to erect the PSA substrate 
peptide for optimal spatial presentation. Thus, the octanethiol 
SAM improves access for the protease to bind to the peptides. 
Cell Culture and Clinical Semen Samples 
LNCaP cells actively secrete PSA into ECF, and the human 
35 CML cells K562 are negative for PSA. Both cell lines are 
maintained in RPMI-1640 with 10% FBS and Ix Pen/Strep, 
at 37° C. with 5% CO z . 10x10 6 cells were cultured overnight 
in 10 ml fresh media. Media from both cultures were col-
lected and PSA activity was measured by fluorescent methods 
40 as described before, and calibrated against commercial PSA 
(Calbiochem, San Diego, Calif.). Briefly, the PSA-binding 
peptides and derivatives with a spacer were chemically syn-
thesized and used to prepare an affinity column, which was 
used to fractionate PSA in seminal plasma. 
45 Purified PSA Preparation and Proteolytic Reaction 
Proteolytically active PSA was purified to homogeneity 
from human seminal plasma by column chromatography, 
eliminating all known PSA complexes and retaining its pro-
tease fraction. Cleavage of the substrate peptide immobilized 
on the NPR nanosensor is performed in a buffer of 50 mM So Tris-HCl, pH 8.0, 100 mM NaCl, and 0.1 mM EDTA, and the 
reaction was monitored in real-time in 37° C. Protease inhibi-
tors (to prevent PSA and Granzyme B degradation) are 
obtained from CalBiochem and added to the reaction follow-
ing the manufacturer's instructions, so that the final reaction 
55 solution contains 5 µM AEBSF, 4.2 nM Aprotinin, 200 nM 
Elastatinal and 10 nM GGACK. The concentration of pro-
teolytically active PSA in the PSA reagent has been prepared 
with a wide range of concentration from 6 pM to 6 nM. 
The present examples, methods, procedures, specific com- 
60 pounds and molecules are meant to exemplify and illustrate 
the invention and should in no way be seen as limiting the 
scope of the invention. Any patents, publications, publicly 
available sequences mentioned in this specification and 
below are indicative of levels of those skilled in the art to 
65 which the invention pertains and are hereby incorporated by 
reference to the same extent as if each was specifically and 
individually incorporated by reference. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 17 
<210> SEQ ID NO 1 
<211> LENGTH: 11 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic PSA-specific peptide substrate 
<400> SEQUENCE: 1 
His Ser Ser Lys Leu Gln Leu Ala Ala Ala Cys 
1 	 5 	 10 
<210> SEQ ID NO 2 
<211> LENGTH: 7 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of cAMP-dependent 
protein kinase 
<400> SEQUENCE: 2 
Leu Arg Arg Ala Ser Leu Gly 
1 	 5 
<210> SEQ ID NO 3 
<211> LENGTH: 9 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of cAMP dependent 
protein kinase (PKA) 
<400> SEQUENCE: 3 
Gly Arg Thr Gly Arg Arg Asn Ser Ile 
1 	 5 
<210> SEQ ID NO 4 
<211> LENGTH: 11 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of protein kinase C 
(PKC) 
<400> SEQUENCE: 4 
Gln Lys Arg Pro Ser Gln Arg Ser Lys Tyr Leu 
1 	 5 	 10 
<210> SEQ ID NO 5 
<211> LENGTH: 7 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of protein kinase 
Akt/PKB 
<400> SEQUENCE: 5 
Arg Pro Arg Ala Ala Thr Phe 
1 	 5 
<210> SEQ ID NO 6 
<211> LENGTH: 12 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of Abl kinase 
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28 
-continued 
<400> SEQUENCE: 6 
Glu Ala Ile Tyr Ala Ala Pro Phe Ala Lys Lys Lys 
1 	 5 	 10 
<210> SEQ ID NO 7 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of 5prime-AMP-
activated protein kinase (AMPK) 
<400> SEQUENCE: 7 
His Met Arg Ser Ala Met Ser Gly Leu His Leu Val Lys Arg Arg 
1 	 5 	 10 	 15 
<210> SEQ ID NO 8 
<211> LENGTH: 13 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of Ca2+/calmodulin-
dependent protein kinase 
<400> SEQUENCE: 8 
Lys Lys Ala Leu Arg Arg Gin Glu Thr Val Asp Ala Leu 
1 	 5 	 10 
<210> SEQ ID NO 9 
<211> LENGTH: 8 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic Peptide substrate of cyclin- 
dependent kinase 2 (cdc2) 
<220> FEATURE: 
<221> NAME/KEY: MOD_RES 
<222> LOCATION: (1)..(1) 
<223> OTHER INFORMATION: ACETYLATION 
<400> SEQUENCE: 9 
Ser Pro Gly Arg Arg Arg Arg Lys 
1 	 5 
<210> SEQ ID NO 10 
<211> LENGTH: 7 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of cyclin-dependent 
kinase 2 (Cdk2) 
<400> SEQUENCE: 10 
His His Ala Ser Pro Arg Lys 
1 	 5 
<210> SEQ ID NO 11 
<211> LENGTH: 10 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of cyclin-dependent 
kinase 5 (Cdk5) 
<400> SEQUENCE: 11 
Pro Lys Thr Pro Lys Lys Ala Lys Lys Leu 
1 	 5 	 10 
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30 
-continued 
<210> SEQ ID NO 12 
<211> LENGTH: 18 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of casein kinase 1 
(CK1) 
<400> SEQUENCE: 12 
Arg Arg Lys Asp Leu His Asp Asp Glu Glu Asp Glu Ala Met Ser Ile 
1 	 5 	 10 	 15 
Thr Ala 
<210> SEQ ID NO 13 
<211> LENGTH: 10 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of CK2 alpha 
subunit or holoenzyme 
<400> SEQUENCE: 13 
Arg Arg Arg Asp Asp Asp Ser Asp Asp Asp 
1 	 5 	 10 
<210> SEQ ID NO 14 
<211> LENGTH: 14 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of DYRK family 
protein kinases 
<400> SEQUENCE: 14 
Lys Lys Ile Ser Gly Arg Leu Ser Pro Ile Met Thr Glu Gin 
1 	 5 	 10 
<210> SEQ ID NO 15 
<211> LENGTH: 26 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of GSK3 alpha and 
beta kinases 
<220> FEATURE: 
<221> NAME/KEY: MOD_RES 
<222> LOCATION: (21)..(21) 
<223> OTHER INFORMATION: PHOSPHORYLATION 
<400> SEQUENCE: 15 
Tyr Arg Arg Ala Ala Val Pro Pro Ser Pro Ser Leu Ser Arg His Ser 
1 	 5 	 10 	 15 
Ser Pro His Gin Ser Glu Asp Glu Glu Glu 
20 	 25 
<210> SEQ ID NO 16 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of Src Kinase 
<400> SEQUENCE: 16 
Lys Val Glu Lys Ile Gly Glu Gly Thr Tyr Gly Val Val Tyr Lys 
1 	 5 	 10 	 15 
<210> SEQ ID NO 17 
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32 
-continued 
<211> LENGTH: 23 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide substrate of checkpoint 
kinases CHK1 and CHK2 
<400> SEQUENCE: 17 
Lys Lys Lys Val Ser Arg Ser Gly Leu Tyr Arg Ser Pro Ser Met Pro 
1 	 5 	 10 	 15 
Glu Asn Leu Asn Arg Pro Arg 
20 
What is claimed is: 
1. A nanoplasmonic resonator (NPR) comprising nano-
disks with alternating dielectric shielding layer(s), having a 
peptide linked to a Ramen active tag, said peptide comprising 
a sequence that can be specifically modified or cleaved by an 
enzyme and where said peptide is conjugated or tethered to 
the surface of the nanoplasmonic resonator, wherein said 
resonator provides sufficient sensitivity to detect modifica-
tion or cleavage of said peptide by said enzyme, and wherein 
said nanodisks comprise a noble metal or transitional metal/ 
metal oxides capable of creating nanoplasmonic resonance. 
2. The resonator of claim 1 wherein the tag is a Raman 
active tag for surface enhanced Raman scattering (SERS) 
detection. 
3. The resonator of claim 1 wherein the tag is a fluorescent 
or other Raman detectable moiety. 
4. The resonator of claim 1, wherein the shielding layer 
comprises a material selected from the group consisting of 
silicon dioxide, quartz, polystyrene, silica, and dextran. 
5. The resonator of claim 4, wherein the nanodisk com-
prises silver. 
6. The resonator of claim 4, wherein the nanodisk com-
prises gold. 
7. The resonator of claim 1, wherein said peptide is the 
peptide R6G-A va-HSSKLQLAAAC-NH2 (SEQ ID NO: 1). 
8. The resonator of claim 1, wherein the nanodisk com-
prises a metal selected from the group consisting of gold, 
silver, platinum, and copper.  
15 
9. The resonator of claim 1, wherein the nanodisk com-
prises platinum or copper. 
10. The resonator of claim 8, wherein the shielding layer-
20 comprises a material selected from the group consisting of 
silicon dioxide, quartz, polystyrene, silica, and dextran. 
11. The resonator of claim 1, wherein the nanodisk com-
prises silver. 
12. The resonator of claim 1, wherein the nanodisk com-
25 prises gold. 
13. The resonator of claim 1, wherein said resonator com-
prises alternating layers of silver and S'0 2 ' 
14. A method useful for in vitro detection and measurement 
of enzymatic activity in a sample, said method comprising: 
30 providing a peptide conjugated nanoplasmonic resonator 
according to any one of claims 1-13; 
contacting said nanoplasmonic resonator with said sample; 
and 
detecting protease cleavage or modification of said peptide 
35 	 by SERS detection, where said nanoplasmonic resona- 
tor provides single-step detection of enzymatic activity. 
15. The method of claim 14, wherein said nanoplasmonic 
resonator provides detection at least nanomolar sensitivity. 
16. The method of claim 14, wherein said nanoplasmonic 
40 resonator provides detection at picomolar sensitivity. 
17. The method of claim 14, wherein the nanodisks are 50 
mil to 500 mil in diameter. 
